Company news

ME Therapeutics Holdings, Inc. news in 2025

ME Therapeutics Holdings, Inc.'s news releases, calls and decks from 2025, newest first.

View company

ME Therapeutics Granted Licence for CD22 Nanobody Asset to Expand Next-Gen In Vivo CAR Cell Therapy Program

October 16, 2025

ME Therapeutics Added to CSE25 Index

October 10, 2025

ME Therapeutics Secures U.S. Patent for Lead Candidate and Advances Broader Therapeutic Programs

September 26, 2025

ME Therapeutics Receives Support to Advance mRNA Therapeutic Candidates for Cancer and Inflammatory Disease

May 21, 2025

ME Therapeutics Announces It Has Engaged Lucosky Brookman LLP to Explore a Listing on the NASDAQ or NYSE

March 3, 2025

ME Therapeutics Announces That Its First Therapeutic mRNA Candidate Shows Encouraging Anti-Cancer Efficacy in Vivo

January 14, 2025

Decks in 2025